Search

Your search keyword '"Tsutsui, Akemi"' showing total 313 results
Start Over Author "Tsutsui, Akemi"
313 results on '"Tsutsui, Akemi"'

1. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Rossari, Federico, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo Alberto, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Soldà, Caterina, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Bruccoleri, Mariangela, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Foti, Silvia, Camera, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

2. ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis

Author

Atsukawa, Masanori, Tsubota, Akihito, Kondo, Chisa, Toyoda, Hidenori, Takaguchi, Koichi, Nakamuta, Makoto, Watanabe, Tsunamasa, Morishita, Asahiro, Tani, Joji, Okubo, Hironao, Hiraoka, Atsushi, Nozaki, Akito, Chuma, Makoto, Kawata, Kazuhito, Uojima, Haruki, Ogawa, Chikara, Asano, Toru, Mikami, Shigeru, Kato, Keizo, Matsuura, Kentaro, Ikegami, Tadashi, Ishikawa, Toru, Tsuji, Kunihiko, Tada, Toshifumi, Tsutsui, Akemi, Senoh, Tomonori, Kitamura, Michika, Okubo, Tomomi, Arai, Taeang, Kohjima, Motoyuki, Morita, Kiyoshi, Akahane, Takehiro, Nishikawa, Hiroki, Iwasa, Motoh, Tanaka, Yasuhito, and Iwakiri, Katsuhiko

Published
2024
Full Text
View/download PDF

3. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

Author

Camera, Silvia, Rimini, Margherita, Rossari, Federico, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Yoo, Changhoon, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Bergamo, Francesca, Salani, Francesca, Marseglia, Mariarosaria, Amadeo, Elisabeth, Vitiello, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Iavarone, Massimo, Cabibbo, Giuseppe, Montes, Margarida, Foschi, Francesco Giuseppe, Vivaldi, Caterina, Lonardi, Sara, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Hiraoka, Atsushi, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Persano, Mara, Foti, Silvia, Piscaglia, Fabio, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2024
Full Text
View/download PDF

4. Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal–gastric varices

Author

Tada, Fujimasa, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Naganuma, Atsushi, Kosaka, Hisashi, Matono, Tomomitsu, Kuroda, Hidekatsu, Yata, Yutaka, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Yokohama, Keisuke, Nishikawa, Hiroki, Imai, Michitaka, Koizumi, Yohei, Nakamura, Shinichiro, Iijima, Hiroko, Kaibori, Masaki, Hiasa, Yoichi, and Kumada, Takashi

Published
2023
Full Text
View/download PDF

5. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Salani, Francesca, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Schirripa, Marta, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

6. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Kawaguchi, Takumi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Cammarota, Antonella, Burgio, Valentina, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

7. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study

Author

Morishita, Asahiro, Oura, Kyoko, Takuma, Kei, Nakahara, Mai, Tadokoro, Tomoko, Fujita, Koji, Tani, Joji, Shi, Tingting, Himoto, Takashi, Tatsuta, Miwa, Moriya, Akio, Senoo, Tomonori, Tsutsui, Akemi, Nagano, Takuya, Takaguchi, Koichi, Ono, Masafumi, and Masaki, Tsutomu

Published
2023
Full Text
View/download PDF

8. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

Author

Rimini, Margherita, Persano, Mara, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Piscaglia, Fabio, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Rimassa, Lorenza, Scartozzi, Mario, Cascinu, Stefano, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

9. Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, and Kumada, Takashi

Published
2023
Full Text
View/download PDF

10. Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Author

Persano, Mara, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Niizeki, Takashi, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Stefanini, Bernardo, Hiraoka, Atsushi, Sho, Takuya, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Campani, Claudia, Amadeo, Elisabeth, Rossari, Federico, Burgio, Valentina, Cascinu, Stefano, Scartozzi, Mario, and Casadei-Gardini, Andrea

Published
2023
Full Text
View/download PDF

11. Correction to: Development and validation of a modified albumin–bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, and Kumada, Takashi

Published
2023
Full Text
View/download PDF

12. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Author

Casadei-Gardini, Andrea, Rimini, Margherita, Tada, Toshifumi, Suda, Goki, Shimose, Shigeo, Kudo, Masatoshi, Cheon, Jaekyung, Finkelmeier, Fabian, Lim, Ho Yeong, Rimassa, Lorenza, Presa, José, Masi, Gianluca, Yoo, Changhoon, Lonardi, Sara, Tovoli, Francesco, Kumada, Takashi, Sakamoto, Naoya, Iwamoto, Hideki, Aoki, Tomoko, Chon, Hong Jae, Himmelsbach, Vera, Pressiani, Tiziana, Montes, Margarida, Vivaldi, Caterina, Soldà, Caterina, Piscaglia, Fabio, Hiraoka, Atsushi, Sho, Takuya, Niizeki, Takashi, Nishida, Naoshi, Steup, Christoph, Iavarone, Massimo, Di Costanzo, Giovanni, Marra, Fabio, Scartozzi, Mario, Tamburini, Emiliano, Cabibbo, Giuseppe, Foschi, Francesco Giuseppe, Silletta, Marianna, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tada, Fujimasa, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Kosaka, Hisashi, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, Burgio, Valentina, Persano, Mara, Della Corte, Angelo, Ratti, Francesca, De Cobelli, Francesco, Aldrighetti, Luca, Cascinu, Stefano, and Cucchetti, Alessandro

Published
2023
Full Text
View/download PDF

13. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Tada, Toshifumi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Shimada, Noritomo, Kawata, Kazuhito, Kosaka, Hisashi, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Kaibori, Masaki, Iijima, Hiroko, Hiasa, Yoichi, and Kumada, Takashi

Published
2022
Full Text
View/download PDF

14. Chronological change in serum albumin as a prognostic factor in patients with hepatocellular carcinoma treated with lenvatinib: proposal of albumin simplified grading based on the modified albumin–bilirubin score (ALBS grade)

Author

Kariyama, Kazuya, Hiraoka, Atsushi, Kumada, Takashi, Yasuda, Satoshi, Toyoda, Hidenori, Tsuji, Kunihiko, Hatanaka, Takeshi, Kakizaki, Satoru, Naganuma, Atsushi, Tada, Toshifumi, Takaguchi, Koichi, Itobayashi, Ei, Ishikawa, Toru, Shimada, Noritomo, Tsutsui, Akemi, Nagano, Takuya, Imai, Michitaka, Nakamura, Shinichiro, Wakuta, Akiko, Miyake, Nozomi, Shiota, Shohei, and Nouso, Kazuhiro

Published
2022
Full Text
View/download PDF

15. SAT-319 RECAM-J 2023-validation of RECAM and development of the japanese version for the diagnosis of DILI

Author

Tanaka, Atsushi, primary, Tsuji, Keiji, additional, Komiyama, Yasuyuki, additional, Tsuruya, Kota, additional, Kakisaka, Keisuke, additional, Tsutsui, Akemi, additional, Ichimoto, Keiko, additional, Ueno, Masayuki, additional, Okazaki, Yuki, additional, Kamimura, Hiroteru, additional, Takai, Atsushi, additional, Yamashiki, Noriyo, additional, Ito, Takanori, additional, Watanabe, Masaaki, additional, Abe, Masanori, additional, and Kagawa, Tatehiro, additional

Published
2024
Full Text
View/download PDF

17. C-reactive protein to albumin ratio predicts survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib

Author

Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Aoki, Tomoko, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Hiasa, Yoichi, and Kudo, Masatoshi

Published
2022
Full Text
View/download PDF

18. The Impact of Cirrhosis and History of Hepatocellular Carcinoma on All-Cause Mortality After Eradication of Hepatitis C Virus in Patients With Chronic Hepatitis C

Author

Toyoda, Hidenori, Atsukawa, Masanori, Uojima, Haruki, Nozaki, Akito, Takaguchi, Koichi, Hiraoka, Atsushi, Itobayashi, Ei, Watanabe, Tsunamasa, Matsuura, Kentaro, Shimada, Noritomo, Abe, Hiroshi, Tsuji, Kunihiko, Itokawa, Norio, Mikami, Shigeru, Ishikawa, Toru, Oikawa, Tsunekazu, Yasuda, Satoshi, Chuma, Makoto, Tsutsui, Akemi, Ikeda, Hiroki, Arai, Taeang, Tsubota, Akihito, Kumada, Takashi, Tanaka, Yasuhito, and Tanaka, Junko

Published
2022
Full Text
View/download PDF

19. Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Foti, Silvia, additional, Camera, Silvia, additional, Stefanini, Bernardo, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei-Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2024
Full Text
View/download PDF

20. Treatment options for solitary hepatocellular carcinoma ≤5 cm: surgery vs. ablation: a multicenter retrospective study

Author

Kariyama, Kazuya, primary, Nouso, Kazuhiro, additional, Hiraoka, Atsushi, additional, Toyoda, Hidenori, additional, Tada, Toshifumi, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Hatanaka, Takeshi, additional, Itobayashi, Ei, additional, Takaguchi, Koichi, additional, Tsutsui, Akemi, additional, Naganuma, Atsushi, additional, Yasuda, Satoshi, additional, Kakizaki, Satoru, additional, Wakuta, Akiko, additional, Shiota, Shohei, additional, Kudo, Masatoshi, additional, and Kumada, Takashi, additional

Published
2024
Full Text
View/download PDF

21. Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study

Author

Tada, Toshifumi, Kumada, Takashi, Okushin, Hiroaki, Tani, Joji, Takaguchi, Koichi, Tsutsui, Akemi, Toyoda, Hidenori, Yasuda, Satoshi, Dohmen, Kazufumi, Hiraoka, Atsushi, Michitaka, Kojiro, Nouso, Kazuhiro, Kariyama, Kazuya, Kim, Soo Ryang, Kim, Soo Ki, Fujioka, Shinichi, Mikami, Shigeru, Watanabe, Yuto, Tamai, Tsutomu, Atsukawa, Masanori, Itokawa, Norio, Tanaka, Hironori, Tsuji, Kunihiko, Ishikawa, Toru, Imai, Michitaka, Itobayashi, Ei, Shibata, Hiroshi, and Shimada, Noritomo

Published
2021
Full Text
View/download PDF

22. RECAM‐J 2023—Validation and development of the Japanese version of RECAM for the diagnosis of drug‐induced liver injury.

Author

Tanaka, Atsushi, Tsuji, Keiji, Komiyama, Yasuyuki, Tsuruya, Kota, Kakisaka, Keisuke, Tsutsui, Akemi, Ichimoto, Keiko, Ueno, Masayuki, Okazaki, Yuki, Kamimura, Hiroteru, Takai, Atsushi, Yamashiki, Noriyo, Ito, Takanori, Watanabe, Masaaki, Abe, Masanori, Harada, Ken‐ichi, and Kagawa, Tatehiro

Subjects
LIVER injuries, DRUG side effects, HEPATITIS A virus, HEPATITIS viruses, VIRAL hepatitis
Abstract

Aim: The diagnosis of drug‐induced liver injury (DILI) is challenging. We modified the revised electronic version of the Roussel Uclaf Causality Assessment Method (RUCAM) for the diagnosis of DILI (RECAM), the scoring system developed in US and Spanish cohorts in 2022, and developed RECAM‐J 2023 to align with the clinical practice in Japan. In the current study, we introduce RECAM‐J 2023 and verify its performance in the context of Japanese patients with DILI. Methods: After translation of RECAM into Japanese, modifications were made to develop RECAM‐J 2023 without any alteration to the scores. To examine the validity and performance of RECAM‐J 2023, clinical information on DILI and non‐DILI cases in Japan were retrospectively collected. The diagnosis of DILI was made by expert's decision. Then we scored each case using RECAM‐J 2023, and calculated area under curve (AUC) values for identification for DILI. Results: We collected data from 538 DILI and 128 non‐DILI cases. The sum of highly probable (HP) and probable (PR) cases categorized by RECAM‐J 2023 were only 206 (38%) in DILI cases. As the primary cause of low scores was the deduction with missing hepatitis virus markers, which is unlikely to be an issue in prospective applications, we rescored without these deductions. At this time, the sum of HP and PR was raised to 421 (78%). The AUCs of RECAM‐J 2023 without deductions were 0.70 and 0.88 for identifying at least HP, and at least PR, respectively. Conclusion: RECAM‐J 2023, when prospectively used without any missing hepatitis virus markers, provides acceptable performance for identifying at least PR DILI cases in Japanese daily clinical practice. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Comparison of six hepatocellular carcinoma prediction models in Japanese patients after sustained virologic response undergoing rigorous surveillance for hepatocellular carcinoma.

Author

Toyoda, Hidenori, Tada, Toshifumi, Uojima, Haruki, Nozaki, Akito, Chuma, Makoto, Takaguchi, Koichi, Hiraoka, Atsushi, Abe, Hiroshi, Itobayashi, Ei, Matsuura, Kentaro, Atsukawa, Masanori, Watanabe, Tsunamasa, Shimada, Noritomo, Nakamuta, Makoto, Kojima, Motoyuki, Tsuji, Kunihiko, Mikami, Shigeru, Ishikawa, Toru, Yasuda, Satoshi, and Tsutsui, Akemi

Subjects
HEPATOCELLULAR carcinoma, JAPANESE people, CHRONIC hepatitis C, PREDICTION models, HEPATITIS C virus
Abstract

Background and Aim: While several predictive models for the development of hepatocellular carcinoma (HCC) have been proposed, including those for patients with chronic hepatitis C virus (HCV) infection who have achieved sustained virologic response (SVR), the best model may differ between regions. We compared the ability of six reported models to stratify the risk of post‐SVR HCC in Japan, where rigorous surveillance and early detection of HCC is common. Methods: A total of 6048 patients with no history of HCC who achieved SVR by oral direct‐acting antiviral drugs were enrolled in this nationwide study. Patients continued HCC surveillance every 6 months after SVR. The incidence of post‐SVR HCC was compared between risk groups using the aMAP score, FIB‐4 index, Tahata model, GAF4 criteria, GES score, and ADRES score. Results: During the observation period with a median duration of 4.0 years after SVR, post‐SVR HCC developed in 332 patients (5.5%). All six models performed significantly at stratifying the incidence of HCC. However, Harrell's C‐index was below 0.8 for all models (range, 0.660–0.748), indicating insufficient stratification ability. Conclusion: Although all six proposed models demonstrated a good ability to predict the development of post‐SVR HCC, their ability to stratify the risk of post‐SVRHCC was unsatisfactory. Further studies are necessary to identify the best model for assessing the risk of post‐SVR HCC in regions where early detection of HCC is common. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Neutrophil–lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis

Author

Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Hirooka, Masashi, Kariyama, Kazuya, Tani, Joji, Atsukawa, Masanori, Takaguchi, Koichi, Itobayashi, Ei, Fukunishi, Shinya, Tsuji, Kunihiko, Ishikawa, Toru, Tajiri, Kazuto, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Ogawa, Chikara, Nishimura, Takashi, Hatanaka, Takeshi, Kakizaki, Satoru, Shimada, Noritomo, Kawata, Kazuhito, Tanaka, Takaaki, Ohama, Hideko, Nouso, Kazuhiro, Morishita, Asahiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Okubo, Tomomi, Arai, Taeang, Imai, Michitaka, Naganuma, Atsushi, Koizumi, Yohei, Nakamura, Shinichiro, Joko, Kouji, Iijima, Hiroko, and Hiasa, Yoichi

Published
2022
Full Text
View/download PDF

25. α‐FAtE: A new predictive score of response to atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma

Author

Rossari, Federico, primary, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Yoo, Changhoon, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa, José, additional, Masi, Gianluca, additional, Bergamo, Francesca, additional, Amadeo, Elisabeth, additional, Vitiello, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Iavarone, Massimo, additional, Cabibbo, Giuseppe, additional, Montes, Margarida, additional, Foschi, Francesco Giuseppe, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Hiraoka, Atsushi, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Persano, Mara, additional, Burgio, Valentina, additional, Piscaglia, Fabio, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, Casadei‐Gardini, Andrea, additional, and Rimini, Margherita, additional

Published
2023
Full Text
View/download PDF

26. Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

Author

Ohama, Hideko, primary, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Naganuma, Atsushi, additional, Kosaka, Hisashi, additional, Matono, Tomomitsu, additional, Kuroda, Hidekatsu, additional, Yata, Yutaka, additional, Tanaka, Hironori, additional, Nishikawa, Hiroki, additional, Shibata, Hiroshi, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Iijima, Hiroko, additional, Kaibori, Masaki, additional, Hiasa, Yoichi, additional, and Kumada, Takashi, additional

Published
2023
Full Text
View/download PDF

27. Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Ohama, Hideko, primary, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Hatanaka, Takeshi, additional, Tani, Joji, additional, Takaguchi, Koichi, additional, Atsukawa, Masanori, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Tajiri, Kazuto, additional, Ishikawa, Toru, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Nishimura, Takashi, additional, Ogawa, Chikara, additional, Satoru, Kakizaki, additional, Shimada, Noritomo, additional, Naganuma, Atsushi, additional, Kawata, Kazuhito, additional, Kosaka, Hisashi, additional, Kuroda, Hidekatsu, additional, Matono, Tomomitsu, additional, Yata, Yutaka, additional, Ochi, Hironori, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Yokohama, Keisuke, additional, Nishikawa, Hiroki, additional, Imai, Michitaka, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Iijima, Hiroko, additional, Kaibori, Masaki, additional, Hiasa, Yoichi, additional, and Kumada, Takashi, additional

Published
2023
Full Text
View/download PDF

28. Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

Author

Tanaka, Kazunari, primary, Tsuji, Kunihiko, additional, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Naganuma, Atsushi, additional, Kosaka, Hisashi, additional, Matono, Tomomitsu, additional, Kuroda, Hidekatsu, additional, Yata, Yutaka, additional, Ohama, Hideko, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Yokohama, Keisuke, additional, Nishikawa, Hiroki, additional, Imai, Michitaka, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Iijima, Hiroko, additional, Kaibori, Masaki, additional, Hiasa, Yoichi, additional, and Kumada, Takashi, additional

Published
2023
Full Text
View/download PDF

29. Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan

Author

Takaguchi, Koichi, Toyoda, Hidenori, Tsutsui, Akemi, Suzuki, Yoshiyuki, Nakamuta, Makoto, Imamura, Michio, Senoh, Tomonori, Nagano, Takuya, Tada, Toshifumi, Tachi, Yoshihiko, Hiraoka, Atsushi, Michitaka, Kojiro, Shibata, Hiroshi, Joko, Kouji, Okubo, Hironao, Tsuji, Kunihiko, Takaki, Shintaro, Watanabe, Tsunamasa, Ogawa, Chikara, Chayama, Kazuaki, Kumada, Takashi, Kudo, Masatoshi, and Kumada, Hiromitsu

Published
2019
Full Text
View/download PDF

30. Platelet–lymphocyte ratio predicts survival in patients with hepatocellular carcinoma who receive lenvatinib: an inverse probability weighting analysis

Author

Tada, Toshifumi, Kumada, Takashi, Hiraoka, Atsushi, Michitaka, Kojiro, Atsukawa, Masanori, Hirooka, Masashi, Tsuji, Kunihiko, Ishikawa, Toru, Takaguchi, Koichi, Kariyama, Kazuya, Itobayashi, Ei, Tajiri, Kazuto, Shimada, Noritomo, Shibata, Hiroshi, Ochi, Hironori, Yasuda, Satoshi, Toyoda, Hidenori, Fukunishi, Shinya, Ohama, Hideko, Kawata, Kazuhito, Nakamura, Shinichiro, Nouso, Kazuhiro, Tsutsui, Akemi, Nagano, Takuya, Itokawa, Norio, Hayama, Korenobu, Arai, Taeang, Imai, Michitaka, Joko, Kouji, Koizumi, Yohei, and Hiasa, Yoichi

Published
2021
Full Text
View/download PDF

31. Relationship between Accurate Diagnosis of Sarcopenia and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab Combination Therapy

Author

Oura, Kyoko, primary, Morishita, Asahiro, additional, Manabe, Takushi, additional, Takuma, Kei, additional, Nakahara, Mai, additional, Tadokoro, Tomoko, additional, Fujita, Koji, additional, Mimura, Shima, additional, Tani, Joji, additional, Ono, Masafumi, additional, Ogawa, Chikara, additional, Moriya, Akio, additional, Senoo, Tomonori, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Takaguchi, Koichi, additional, Himoto, Takashi, additional, and Masaki, Tsutomu, additional

Published
2023
Full Text
View/download PDF

32. Lenvatinib as Second-Line Treatment after Atezolizumab plus Bevacizumab for Unresectable Hepatocellular Carcinoma: Clinical Results Show Importance of Hepatic Reserve Function

Author

Hiraoka, Atsushi, primary, Kumada, Takashi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Naganuma, Atsushi, additional, Kosaka, Hisashi, additional, Matono, Tomomitsu, additional, Kuroda, Hidekatsu, additional, Yata, Yutaka, additional, Ohama, Hideko, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Yokohama, Keisuke, additional, Imai, Michitaka, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Iijima, Hiroko, additional, Kaibori, Masaki, additional, and Hiasa, Yoichi, additional

Published
2023
Full Text
View/download PDF

33. Association of PPI and antibiotics with the clinical outcomes of HCC patients receiving atezolizumab and bevacizumab: A multicenter analysis

Author

Hatanaka, Takeshi, primary, Kakizaki, Satoru, additional, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Yata, Yutaka, additional, Tanaka, Takaaki, additional, Ohama, Hideko, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, and Kumada, Takashi, additional

Published
2023
Full Text
View/download PDF

34. Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Author

Rimini, Margherita, primary, Persano, Mara, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Presa Ramos, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Stefanini, Bernardo, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Montes, Margarida, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Hiraoka, Atsushi, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Burgio, Valentina, additional, Della Corte, Angelo, additional, Ratti, Francesca, additional, De Cobelli, Francesco, additional, Aldrighetti, Luca, additional, Scartozzi, Mario, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2023
Full Text
View/download PDF

35. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study

Author

Morishita, Asahiro, primary, Oura, Kyoko, additional, Takuma, Kei, additional, Nakahara, Mai, additional, Tadokoro, Tomoko, additional, Fujita, Koji, additional, Tani, Joji, additional, Shi, Tingting, additional, Himoto, Takashi, additional, Tatsuta, Miwa, additional, Moriya, Akio, additional, Senoo, Tomonori, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Takaguchi, Koichi, additional, Ono, Masafumi, additional, and Masaki, Tsutomu, additional

Published
2022
Full Text
View/download PDF

36. Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Author

Tada, Toshifumi, primary, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, and Hiasa, Yoichi, additional

Published
2022
Full Text
View/download PDF

37. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

Author

Persano, Mara, primary, Rimini, Margherita, additional, Tada, Toshifumi, additional, Suda, Goki, additional, Shimose, Shigeo, additional, Kudo, Masatoshi, additional, Cheon, Jaekyung, additional, Finkelmeier, Fabian, additional, Lim, Ho Yeong, additional, Rimassa, Lorenza, additional, Presa, José, additional, Masi, Gianluca, additional, Yoo, Changhoon, additional, Lonardi, Sara, additional, Tovoli, Francesco, additional, Kumada, Takashi, additional, Sakamoto, Naoya, additional, Iwamoto, Hideki, additional, Aoki, Tomoko, additional, Chon, Hong Jae, additional, Himmelsbach, Vera, additional, Pressiani, Tiziana, additional, Kawaguchi, Takumi, additional, Montes, Margarida, additional, Vivaldi, Caterina, additional, Soldà, Caterina, additional, Piscaglia, Fabio, additional, Hiraoka, Atsushi, additional, Sho, Takuya, additional, Niizeki, Takashi, additional, Nishida, Naoshi, additional, Steup, Christoph, additional, Iavarone, Massimo, additional, Di Costanzo, Giovanni, additional, Marra, Fabio, additional, Scartozzi, Mario, additional, Tamburini, Emiliano, additional, Cabibbo, Giuseppe, additional, Foschi, Francesco Giuseppe, additional, Silletta, Marianna, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tada, Fujimasa, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Kosaka, Hisashi, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, Cammarota, Antonella, additional, Burgio, Valentina, additional, Cascinu, Stefano, additional, and Casadei-Gardini, Andrea, additional

Published
2022
Full Text
View/download PDF

38. Nutritional status is associated with prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab

Author

Tada, Toshifumi, primary, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Hirooka, Masashi, additional, Takaguchi, Koichi, additional, Atsukawa, Masanori, additional, Fukunishi, Shinya, additional, Itobayashi, Ei, additional, Tsuji, Kunihiko, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Ishikawa, Toru, additional, Yasuda, Satoshi, additional, Ogawa, Chikara, additional, Toyoda, Hidenori, additional, Hatanaka, Takeshi, additional, Nishimura, Takashi, additional, Kakizaki, Satoru, additional, Kawata, Kazuhito, additional, Shimada, Noritomo, additional, Tada, Fujimasa, additional, Nouso, Kazuhiro, additional, Tsutsui, Akemi, additional, Ohama, Hideko, additional, Morishita, Asahiro, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Kosaka, Hisashi, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Nakamura, Shinichiro, additional, Koizumi, Yohei, additional, Matono, Tomomitsu, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, and Hiasa, Yoichi, additional

Published
2022
Full Text
View/download PDF

39. Development and validation of a modified albumin-bilirubin grade and α-fetoprotein score (mALF score) for hepatocellular carcinoma patients receiving atezolizumab and bevacizumab.

Author

Hatanaka, Takeshi, primary, Kakizaki, Satoru, additional, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Kosaka, Hisashi, additional, Tanaka, Takaaki, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, and Kumada, Takashi, additional

Published
2022
Full Text
View/download PDF

40. Identification of CT Values That Could Be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma after Lenvatinib Treatment

Author

Chuma, Makoto, primary, Yokoo, Hideki, additional, Hiraoka, Atsushi, additional, Ueda, Kazuhiko, additional, Yokoyama, Takahiro, additional, Tsuji, Kunihiko, additional, Shimada, Noritomo, additional, Uojima, Haruki, additional, Kobayashi, Satoshi, additional, Hattori, Nobuhiro, additional, Okubo, Tomomi, additional, Atsukawa, Masanori, additional, Ishikawa, Toru, additional, Takaguchi, Koichi, additional, Tsutsui, Akemi, additional, Toyoda, Hidenori, additional, Tada, Toshifumi, additional, Saito, Yoshinori, additional, Hirose, Shunji, additional, Tanaka, Takaaki, additional, Takeda, Kazuhisa, additional, Otani, Masako, additional, Sekikawa, Zenjiro, additional, Watanabe, Tsunamasa, additional, Hidaka, Hisashi, additional, Morimoto, Manabu, additional, Numata, Kazushi, additional, Kagawa, Tatehiro, additional, Sakamoto, Michiie, additional, Kumada, Takashi, additional, and Maeda, Shin, additional

Published
2022
Full Text
View/download PDF

41. Assessment of Ultra-Early-Stage Liver Fibrosis in Human Non-Alcoholic Fatty Liver Disease by Second-Harmonic Generation Microscopy

Author

Minamikawa, Takeo, Hase, Eiji, Ichimura-Shimizu, Mayuko, Morimoto, Yuki, Suzuki, Akihiro, Yasui, Takeshi, Nakamura , Satoko, Tsutsui, Akemi, Takaguchi, Koichi, Tsuneyama, Koichi, Minamikawa, Takeo, Hase, Eiji, Ichimura-Shimizu, Mayuko, Morimoto, Yuki, Suzuki, Akihiro, Yasui, Takeshi, Nakamura , Satoko, Tsutsui, Akemi, Takaguchi, Koichi, and Tsuneyama, Koichi

Abstract

Non-alcoholic fatty liver disease (NAFLD) is associated with the chronic progression of fibrosis. In general, the progression of liver fibrosis is determined by a histopathological assessment with a collagen-stained section; however, the ultra-early stage of liver fibrosis is challenging to identify because of the low sensitivity in the collagen-selective staining method. In the present study, we demonstrate the feasibility of second-harmonic generation (SHG) microscopy in the histopathological diagnosis of the liver of NAFLD patients for the quantitative assessment of the ultra-early stage of fibrosis. We investigated four representative NAFLD patients with early stages of fibrosis. SHG microscopy visualised well-matured fibrotic structures and early fibrosis diffusely involving liver tissues, whereas early fibrosis is challenging to be identified by conventional histopathological methods. Furthermore, the SHG emission directionality analysis revealed the maturation of each collagen fibre of each patient. As a result, SHG microscopy is feasible for assessing liver fibrosis on NAFLD patients, including the ultra-early stage of liver fibrosis that is difficult to diagnose by the conventional histopathological method. The assessment method of the ultra-early fibrosis by using SHG microscopy may serve as a crucial means for pathological, clinical, and prognostic diagnosis of NAFLD patients.

Published
2022

43. Identification of CT Attenuation Values that Could be Predictive of Necrosis (N-CTav) in Hepatocellular Carcinoma Tumors after Lenvatinib Treatment and the Association between the N-CTav Occupancy Rate in the Tumor and Maintenance of Complete Response with Lenvatinib Treatment

Author

Chuma, Makoto, primary, Yokoo, Hideki, additional, Hiraoka, Atsushi, additional, Ueda, Kazuhiko, additional, Yokoyama, Takahiro, additional, Tsuji, Kunihiko, additional, Shimada, Noritomo, additional, Uojima, Haruki, additional, Kobayashi, Satoshi, additional, Hattori, Nobuhiro, additional, Okubo, Tomomi, additional, Atsukawa, Masanori, additional, Ishikawa, Toru, additional, Takaguchi, Koichi, additional, Tsutsui, Akemi, additional, Toyoda, Hidenori, additional, Tada, Toshifumi, additional, Saito, Yoshinori, additional, Hirose, Shunji, additional, Tanaka, Takaaki, additional, Takeda, Kazuhisa, additional, Otani, Masako, additional, Sekikawa, Zenjiro, additional, Watanabe, Tsunamasa, additional, Hidaka, Hisashi, additional, Morimoto, Manabu, additional, Numata, Kazushi, additional, Kagawa, Tatehiro, additional, Sakamoto, Michiie, additional, Kumada, Takashi, additional, and Maeda, Shin, additional

Published
2022
Full Text
View/download PDF

44. Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A multicenter retrospective study

Author

Hatanaka, Takeshi, primary, Kakizaki, Satoru, additional, Hiraoka, Atsushi, additional, Tada, Toshifumi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Ogawa, Chikara, additional, Nishimura, Takashi, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Kosaka, Hisashi, additional, Tanaka, Takaaki, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Joko, Kouji, additional, Kaibori, Masaki, additional, Iijima, Hiroko, additional, Hiasa, Yoichi, additional, and Kumada, Takashi, additional

Published
2022
Full Text
View/download PDF

45. Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era

Author

Hiraoka, Atsushi, primary, Kumada, Takashi, additional, Kariyama, Kazuya, additional, Toyoda, Hidenori, additional, Yasuda, Satoshi, additional, Tsuji, Kunihiko, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Naganuma, Atsushi, additional, Ishikawa, Toru, additional, Tada, Toshifumi, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Shimada, Noritomo, additional, Shibata, Hiroshi, additional, Tanaka, Takaaki, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Imai, Michitaka, additional, Nakamura, Shinichiro, additional, and Nouso, Kazuhiro, additional

Published
2021
Full Text
View/download PDF

46. C-Reactive Protein to Albumin Ratio Predicts Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Analysis

Author

Tada, Toshifumi, primary, Kumada, Takashi, additional, Hiraoka, Atsushi, additional, Hirooka, Masashi, additional, Kariyama, Kazuya, additional, Tani, Joji, additional, Atsukawa, Masanori, additional, Takaguchi, Koichi, additional, Itobayashi, Ei, additional, Fukunishi, Shinya, additional, Tsuji, Kunihiko, additional, Ishikawa, Toru, additional, Tajiri, Kazuto, additional, Ochi, Hironori, additional, Yasuda, Satoshi, additional, Toyoda, Hidenori, additional, Hatanaka, Takeshi, additional, Kakizaki, Satoru, additional, Shimada, Noritomo, additional, Kawata, Kazuhito, additional, Tanaka, Takaaki, additional, Ohama, Hideko, additional, Nouso, Kazuhiro, additional, Morishita, Asahiro, additional, Tsutsui, Akemi, additional, Nagano, Takuya, additional, Itokawa, Norio, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Imai, Michitaka, additional, Naganuma, Atsushi, additional, Aoki, Tomoko, additional, Koizumi, Yohei, additional, Nakamura, Shinichiro, additional, Joko, Kouji, additional, Hiasa, Yoichi, additional, and Kudo, Masatoshi, additional

Published
2021
Full Text
View/download PDF

48. Clinical outcomes of antithrombin III‐based therapy for patients with portal vein thrombosis: A retrospective, multicenter study.

Author

Hayama, Korenobu, Atsukawa, Masanori, Tsubota, Akihito, Kondo, Chisa, Iwasa, Motoh, Hasegawa, Hiroshi, Takaguchi, Koichi, Tsutsui, Akemi, Uojima, Haruki, Hidaka, Hisashi, Okubo, Hironao, Suzuki, Tatsuya, Matsuura, Kentaro, Tada, Toshifumi, Kawabe, Naoto, Tani, Joji, Morishita, Asahiro, Ishikawa, Toru, Arase, Yoshitaka, and Furuichi, Yoshihiro

Subjects
PATIENT portals, PORTAL vein, THROMBOSIS, TREATMENT effectiveness, THROMBOLYTIC therapy
Abstract

Aim: The association between thrombolytic therapy and the outcome in patients with portal vein thrombosis (PVT) remains controversial. This study aimed to evaluate the outcome in patients with PVT who received antithrombin III‐based therapy. Methods: This study was a retrospective, multicenter study to investigate the liver‐related events and the survival rates in 240 patients with PVT who received the therapy. Results: The patients comprised 151 men and 89 women, with a median age of 69 years. The rate of favorable response, defined as maximum area of PVT changed to ≤75%, was 67.5% (162/240). The cumulative rates of liver‐related events at 1, 2, and 3 years were 38.2%, 53.9%, and 68.5%, respectively. The multivariate analysis showed that viable hepatocellular carcinoma, absence of maintenance therapy, non‐responder, and PVT progression were significantly associated with liver‐related events. The PVT progression was observed in 23.3% (56/240). The multivariate analysis identified older age, absence of maintenance therapy, and non‐responder as independent factors associated with PVT progression. The multivariate analysis revealed that younger age, no hepatocellular carcinoma, presence of maintenance therapy, and lower Model for End‐stage Liver Disease‐Sodium score significantly contributed to 3‐year survival. Of the 240 patients, 13 (8.9%) prematurely discontinued treatment due to any adverse events. Conclusions: This study suggests that maintenance therapy, favorable response, and absence of PVT progression may suppress or control liver‐related events in antithrombin III‐based therapy for patients with PVT. Specifically, maintenance therapy could suppress not only liver‐related events, but also PVT progression and improve the prognosis. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. The prognosis of elderly patients with hepatocellular carcinoma: A multi‐center 19‐year experience in Japan.

Author

Hatanaka, Takeshi, Kakizaki, Satoru, Hiraoka, Atsushi, Kariyama, Kazuya, Tsuji, Kunihiko, Ishikawa, Toru, Toyoda, Hidenori, Yasuda, Satoshi, Naganuma, Atsushi, Tada, Toshifumi, Takaguchi, Koichi, Tsutsui, Akemi, Itobayashi, Ei, Shimada, Noritomo, Shibata, Hiroshi, Tanaka, Takaaki, Nagano, Takuya, Imai, Michitaka, Nakamura, Shinichiro, and Nouso, Kazuhiro

Subjects
OLDER patients, HEPATOCELLULAR carcinoma, OVERALL survival, PROGNOSIS
Abstract

Aims: This retrospective study compared the survival between elderly and non‐elderly patients. Methods: A total of 5545 treatment‐naive patients with hepatocellular carcinoma (HCC) who visited 7 different hospitals from January 2000 to December 2018 were included. Patients ≥80 years old were defined as elderly patients. We divided the patients into three groups based on the timing of the initial treatment: Early, middle, and late periods defined as 2000 to 2005, 2006 to 2012, and 2013 to 2018, respectively. Results: There were 132 (8.9%), 405 (17.5%), and 388 (22.2%) elderly patients in the early, middle, and late period, respectively, showing a significant increase over time (p < 0.001). In both elderly and non‐elderly patients, the median albumin‐bilirubin score significantly improved over time and the diagnosis of HCC was made slightly earlier over time. The median overall survival (OS) in elderly patients was 52.8, 42.0, and 45.6 months in the early, middle, and late period, respectively, without a significant improvement (p = 0.17) whereas the OS in non‐elderly patients was significantly improved (p < 0.001). The percentage of elderly patients receiving curative treatments did not significantly increase (p = 0.43), while that of non‐elderly patients did (p = 0.017). Non‐liver‐related death in elderly patients significantly differed among periods (p = 0.023), while liver‐related death did not (p = 0.050). Liver‐ and non‐liver‐related death in non‐elderly patients significantly differed among periods (p < 0.001, p = 0.005). Conclusions: Survival in elderly patients was not improved despite an improvement in their liver function. Curative treatments should be conducted when appropriate after evaluating each elderly patient. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C

Author

Atsukawa, Masanori, primary, Tsubota, Akihito, additional, Kondo, Chisa, additional, Uchida-Kobayashi, Sawako, additional, Takaguchi, Koichi, additional, Tsutsui, Akemi, additional, Nozaki, Akito, additional, Chuma, Makoto, additional, Hidaka, Isao, additional, Ishikawa, Tsuyoshi, additional, Iwasa, Motoh, additional, Tamai, Yasuyuki, additional, Tobari, Maki, additional, Matsuura, Kentaro, additional, Nagura, Yoshihito, additional, Abe, Hiroshi, additional, Kato, Keizo, additional, Suzuki, Kenta, additional, Okubo, Tomomi, additional, Arai, Taeang, additional, Itokawa, Norio, additional, Toyoda, Hidenori, additional, Enomoto, Masaru, additional, Tamori, Akihiro, additional, Tanaka, Yasuhito, additional, Kawada, Norifumi, additional, Takei, Yoshiyuki, additional, and Iwakiri, Katsuhiko, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results